In summary , the current meta- analysis demonstrated that melatonin supplementation  significantly decreased SBP and DBP in patients with metabolic disorders .
The current systematic review and meta- analysis of r and omized controlled trials ( RCTs ) was conducted to evaluate the potential effect of melatonin supplementation on  blood pressure in patients with metabolic disorders .
Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin.
Glycemic control and prevention of secondary complications are the most important goals of using pharmacologic treatment of diabetes mellitus ( DM ) . The inadequate responses to oral hypoglycemic agents may be attributed to inadequate postreceptor events even when insulin levels are quite sufficient , and associated with oxidative stress induced by long-term hyperglycemia . The administration of antioxidants such as melatonin and zinc may improve tissue responses to insulin and increase the efficacy of drugs , e.g. metformin , which act through this pathway . This project was design ed to evaluate the effects of melatonin and zinc on the lipid profile and renal function in type 2 DM patients poorly controlled with metformin .  A placebo-controlled , double-blind clinical trial was performed in which 46 type 2 diabetic patients were selected and allocated into three groups . These groups were treated with single daily oral doses of both 10 mg of melatonin and 50 mg of zinc acetate alone : 10 mg of melatonin and 50 mg of zinc acetate in addition to the regularly used metformin or placebo , given at bedtime for 90 days . Fasting lipid profiles and microalbuminuria ( MAU ) were measured before initiating the treatments ( zero time ) and after 30 and 90 days of treatment . Daily administration of melatonin and zinc improved the impaired lipid profile and decreased the level of MAU ; the addition of this treatment regimen in combination with metformin improved the tissue responses to this oral hypoglycemic agent . In conclusion , the combination of melatonin and zinc acetate , when used alone or in combination with metformin , improves DM-related complications such as the impaired lipid profile and MAU in type 2 DM patients
In summary , the current meta- analysis demonstrated that melatonin supplementation  significantly decreased SBP and DBP in patients with metabolic disorders .
The current systematic review and meta- analysis of r and omized controlled trials ( RCTs ) was conducted to evaluate the potential effect of melatonin supplementation on  blood pressure in patients with metabolic disorders .